Verici Dx (Verici Dx) Total Assets

: $9.35 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Verici Dx's Total Assets for the quarter that ended in Jun. 2023 was $9.35 Mil.

During the past 12 months, Verici Dx's average Total Assets Growth Rate was 6.20% per year.

Total Assets is connected with ROA %. Verici Dx's annualized ROA % for the quarter that ended in Jun. 2023 was -89.15%. Total Assets is also linked to Revenue through Asset Turnover. Verici Dx's Asset Turnover for the quarter that ended in Jun. 2023 was 0.00.

Verici Dx Total Assets Historical Data

The historical data trend for Verici Dx's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Total Assets

20.31

13.79

14.31

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Total Assets	17.77	13.79	19.49	14.31	9.35

Verici Dx Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Verici Dx's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	11.509	+	2.796
	=	14.31

Verici Dx's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2023 )	+	Total Liabilities (Q: Jun. 2023 )
	=	6.688	+	2.665
	=	9.35

Verici Dx (OTCPK:VRCDF) Total Assets Explanation

Total Assets is connected with ROA %.

Verici Dx's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %	=	Net Income (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	-10.546	/	( (14.305	+	9.353)	/ 2 )
	=	-10.546	/	11.829
	=	-89.15 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Verici Dx's Asset Turnover for the quarter that ended in Jun. 2023 is

	Asset Turnover
=	Revenue (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
=	0.019	/	( (14.305	+	9.353)	/ 2 )
=	0.019	/	11.829
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Verici Dx Total Assets Related Terms

Thank you for viewing the detailed overview of Verici Dx's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines